Alpha 2.0
Login Register
» Authors » Paul Audhya

Paul Audhya

Explore the profile of Paul Audhya including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 1602
Followers 0
Related Specialties
Nephrology
General Medicine
Pharmacology
Top 10 Co-Authors
David G Warnock
Christoph Wanner
Leslie A McClure
George Howard
Janet Wittes
Mary Cushman
Yili Pritchett
Debra Scarlata
Rajiv Agarwal
Hans-Henrik Parving
Published In
Am J Nephrol
J Am Med Dir Assoc
N Engl J Med
J Am Soc Nephrol
Nephrol Dial Transplant
Affiliations
Soon will be listed here.
Recent Articles
1.
On-demand treatment of hereditary angioedema attacks: Patient-reported utilization, barriers, and outcomes
Christiansen S, OConnor M, Craig T, Radojicic C, Wedner H, Danese S, et al.
Ann Allergy Asthma Immunol . 2024 Dec; PMID: 39694088
Background: Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of subcutaneous and submucosal swelling. Objective: To investigate real-world timing, potential barriers, and impact of delaying on-demand treatment (OD) of...
2.
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
Petersen R, Fijen L, Apfelbacher C, Magerl M, Weller K, Aberer W, et al.
J Allergy Clin Immunol Pract . 2024 Apr; 12(6):1614-1621. PMID: 38609017
Background: Clinical trials investigating drugs for the acute treatment of hereditary angioedema attacks have assessed many different outcomes. This heterogeneity limits the comparability of trial results and may lead to...
3.
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation
Berkers G, van der Meer R, Heijerman H, Beekman J, Boj S, Vries R, et al.
J Cyst Fibros . 2020 Nov; 20(5):761-767. PMID: 33249003
Background: Previous in vitro organoid data showed A455E-CFTR, a rare CFTR mutation with 4.1% prevalence in the Netherlands, responds to lumacaftor/ivacaftor (LUM/IVA). We explored LUM/IVA's clinical efficacy in people with...
4.
Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study
Dellanna F, Fluck R, Lonnemann G, Wild C, Iwanowitsch A, Meissner R, et al.
Clin Nephrol . 2015 Sep; 84(5):280-8. PMID: 26396097
Background: Epoetin-zeta (epoetin-ζ) (sold as Retacrit™/Silapo™) is a biologic product that was approved by the European Medicines Agency in 2007 after demonstrating biosimilarity to its reference product epoetin-α (Eprex™), based...
5.
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease
de Zeeuw D, Akizawa T, Audhya P, Bakris G, Chin M, Christ-Schmidt H, et al.
N Engl J Med . 2013 Nov; 369(26):2492-503. PMID: 24206459
Background: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further...
6.
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial
Lambers Heerspink H, Chertow G, Akizawa T, Audhya P, Bakris G, Goldsberry A, et al.
Nephrol Dial Transplant . 2013 Oct; 28(11):2841-50. PMID: 24169612
Background: Type 2 diabetes mellitus (T2DM) is the most important contributing cause of end-stage renal disease (ESRD) worldwide. Bardoxolone methyl, a nuclear factor-erythroid-2-related factor 2 activator, augments estimated glomerular filtration....
7.
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris G, Chin M, et al.
Am J Nephrol . 2013 Mar; 37(3):212-22. PMID: 23467003
Background: Chronic kidney disease (CKD) associated with type 2 diabetes mellitus constitutes a global epidemic complicated by considerable renal and cardiovascular morbidity and mortality, despite the provision of inhibitors of...
8.
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
Ketteler M, Martin K, Cozzolino M, Goldsmith D, Sharma A, Khan S, et al.
Nephrol Dial Transplant . 2011 Sep; 27(5):1942-9. PMID: 21931122
Background: Paricalcitol and cinacalcet are common therapies for patients on haemodialysis with secondary hyperparathyroidism (SHPT). We conducted a multi-centre study in 12 countries to compare the safety and efficacy of...
9.
Bardoxolone methyl and kidney function in CKD with type 2 diabetes
Pergola P, Raskin P, Toto R, Meyer C, Huff J, Grossman E, et al.
N Engl J Med . 2011 Jun; 365(4):327-36. PMID: 21699484
Background: Chronic kidney disease (CKD) associated with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative stress contributing to disease progression. Bardoxolone methyl, an...
10.
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease
Pritchett Y, Jemiai Y, Chang Y, Bhan I, Agarwal R, Zoccali C, et al.
Clin Trials . 2011 Apr; 8(2):165-74. PMID: 21478328
Background: Chronic kidney disease is associated with a marked increase in risk for left ventricular hypertrophy and cardiovascular mortality compared with the general population. Therapy with vitamin D receptor activators...